Agentic Workflow for Bridging R&D and Commercial Teams with Shared Synthetic Data

Manual data procurement, legal review, and IRB approvals for cross-departmental data sharing create massive bottlenecks. This workflow generates compliant, statistically representative synthetic cohorts on-demand, turning a multi-quarter process into a self-service operation completed in days. The time-to-insight acceleration directly translates into faster trial design and market strategy cycles.

R&D uses pristine clinical data, while Commercial models rely on claims and demographic proxies, creating misaligned forecasts. This workflow generates synthetic patients enriched with both clinical variables (e.g., lab values, progression) and commercial variables (e.g., payer mix, geographic access). This unified asset ensures market access simulations and trial feasibility analyses are built from the same underlying patient population, reducing strategic misalignment.

Sharing real patient data between departments triggers extensive legal agreements and privacy reviews. By operating exclusively on synthetic data with proven re-identification risk scores (k-anonymity, l-diversity), the workflow creates a low-friction data sharing environment. Governance is baked into the generation pipeline via differential privacy controls and automated audit logging, dramatically reducing legal and compliance team burden.

Commercial forecasts often fail to account for complex patient comorbidities and treatment pathways. This workflow uses agentic validation and clinical knowledge graphs to ensure synthetic cohorts reflect realistic disease progression and care patterns. Feeding these cohorts into market access models (e.g., in R or Python) yields more accurate predictions of therapy adoption, market share, and revenue, protecting launch investments.

Evaluating 'what-if' scenarios for trial design or commercial strategy requires new data slices, which are slow to procure. This workflow enables instant generation of tailored cohorts (e.g., 'patients aged 65+ with biomarker X in Europe'). Teams can model multiple strategic scenarios in parallel, compressing portfolio decision cycles from weeks to days and enabling more agile resource allocation.

Beyond a one-off project, this workflow establishes a continuous synthetic data pipeline integrated with source systems (EHR, CRM, claims). It becomes a scalable, depreciable asset. New therapy areas or regional expansions can leverage the same architecture, avoiding rebuilds and creating compounding operational leverage across the R&D and Commercial organizations.

This specialized agent orchestrates the initial requirement-gathering phase by interviewing stakeholders in R&D (e.g., biostatisticians, clinical scientists) and Commercial (e.g., market access, forecasting) via structured prompts. It synthesizes disparate needs—from clinical trial covariates to commercial variables like payer mix and regional adoption rates—into a unified data specification. This eliminates months of manual workshops and document reconciliation, creating a single source of truth for the synthetic cohort's target distribution.

The core engine uses conditional generative models (e.g., GANs, diffusion) trained on real-world data to produce statistically realistic patient records. It is architecturally configured to accept the unified specification, ensuring outputs reflect both clinical (e.g., disease severity, lab values) and commercial (e.g., insurance type, geographic density) attributes. This component runs in a privacy-preserving environment, often using differential privacy, and integrates with high-performance computing clusters to generate cohorts of 10k-100k patients on demand.

A critical sub-workflow that injects commercial realism into clinically generated data. It uses agentic logic to apply business rules—such as mapping diagnosis codes to formulary tiers, simulating regional referral patterns, or modeling time-to-treatment adoption based on historical launch data. This layer connects to external data APIs (e.g., IQVIA, claims data aggregates) to ground the synthesis in real market dynamics, ensuring the synthetic asset is actionable for forecasting and go-to-market simulations.

An automated quality gate employing a multi-agent system to validate the synthetic cohort. One agent subset runs statistical tests (KS, propensity score) to ensure clinical plausibility against holdout real data. A parallel agent group validates commercial logic, checking for contradictions (e.g., a pediatric patient with a Medicare plan). Failed cohorts trigger regeneration with updated parameters. This replaces manual, sample-based QA and provides defensible audit trails for governance committees.

This component manages the secure provisioning of the approved synthetic asset. It integrates with enterprise IAM (e.g., Okta, Azure AD) to enforce role-based access: R&D teams receive data in analysis-ready formats (e.g., SAS, R) with full clinical variables, while Commercial teams receive a masked view focused on commercial attributes. All access, queries, and derivative uses are logged to an immutable ledger (e.g., via a data catalog like Collibra) for compliance with internal data use agreements and external regulations.

A feedback and observability agent that tracks how the synthetic data asset is utilized across departments. It monitors query patterns, model development projects in R&D, and simulation runs in Commercial to quantify operational impact—such as reduced protocol amendment cycles or faster market model iterations. This data feeds into a dashboard showing tangible ROI (e.g., $XM in accelerated trial timelines, Y% reduction in forecast error), justifying ongoing investment and guiding pipeline enhancements.